The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1583
ISSUE1583
October 21, 2019
Oral Semaglutide (Rybelsus) for Type 2 Diabetes
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Oral Semaglutide (Rybelsus) for Type 2 Diabetes
October 21, 2019 (Issue: 1583)
An oral formulation of the glucagon-like peptide-1
(GLP-1) receptor agonist semaglutide (Rybelsus –
Novo Nordisk) has been approved by the FDA
for once-daily treatment of type 2 diabetes in
adults. Semaglutide, which has been available in
a...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.